Personalized treatment for thyroid disorders using a wearable device
Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease
This study is testing a new wearable device that measures radiation exposure in real-time to see if it can help people with thyroid disorders get better treatment during their radioiodine therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 21 Years to 65 Years |
| Sex | All |
| Sponsor | Johns Hopkins University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT03517579 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of the Collar Therapy Indicator (CoTI), a wearable device designed to continuously measure radiation exposure in patients undergoing radioiodine treatment for thyroid disorders. By providing real-time data on radiation absorption, the CoTI aims to improve the accuracy of dosage estimates for patients with Graves' disease and differentiated thyroid cancer. The study seeks to address the limitations of traditional methods that rely on limited time-point measurements, which can lead to inadequate treatment or overtreatment. Ultimately, the goal is to optimize individual patient care and minimize side effects associated with radioiodine therapy.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed Graves' disease or those with intermediate to high-risk differentiated thyroid cancer requiring radioiodine treatment.
Not a fit: Patients with cervical spine diseases or those unable to understand simple instructions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment plans for patients with thyroid disorders, reducing the risk of treatment failure and long-term complications.
How similar studies have performed: While the use of wearable radiation detection technology is novel, previous studies have indicated that personalized approaches to radioiodine treatment can improve patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group I * Patients with Graves' disease confirmed by laboratory testing. * Patients able to understand English and able to follow instructions. Group II * Patients with intermediate and high risk differentiated thyroid cancer requiring radioiodine remnant ablation or moderately high dose I-131 for treatment of residual cervical disease. * Persons able to understand simple English and able to follow instructions. Exclusion Criteria: * Patients with diseases involving cervical spine, such as spondylosis and severe degenerative joint disease. * Pregnant Women, elderly and persons unable to understand simple instructions
Where this trial is running
Baltimore, Maryland
- Johns Hopkins Hospital — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Prasanna Santhanam, MBBS, MD — Johns Hopkins University
- Study coordinator: Prasanna Santhanam, MBBS, MD
- Email: psantha1@jhmi.edu
- Phone: 410-550-6023
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.